Virus Like Particles

ALL Virus Like Particles

Filter By

Product Type

Product Category

Target Pathogen

Product Target

Application

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Gamma (P.1)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Gamma (P.1) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike D138Y, Spike D614G, Spike E484K, Spike H655Y, Spike K417T, Spike L18F, Spike N501Y, Spike P26S, Spike R190S, Spike T20N, Spike T1027I, Spike V1176F Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Kappa (B.1.617.1) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike E154K, Spike L452R, Spike E484Q, Spike D614G, Spike P681R, Spike Q1071H Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,340.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Lambda (C.37)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Lambda (C.37) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike G75V, Spike T76I, Spike R246N, Spike del247/253, Spike L452Q, Spike F490S, Spike D614G, Spike T859N Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Mu (B.1.621)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Mu (B.1.621) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T95I, Spike Y144S, Spike Y145N, Spike R346K, Spike E484K, Spike N501Y, Spike D614G, Spike P681H, Spike D950N Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Omicron (B.1.1.529)

SARS-CoV-2, Virus Like Particles (Ha-CoV2) Omicron (B.1.1.529) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike A67V, Spike H69del,Spike V70del, Spike T95I, Spike G142D, Spike V143del, Spike Y144del, Spike Y145del, Spike N211del, Spike L212I, Spike ins214EPE, Spike G339D, Spike S371L, Spike S373P, Spike S375F, Spike K417N, Spike N440K, Spike G446S, Spike S477N, Spike T478K, Spike E484A, Spike Q493R, Spike G496S, Spike Q498R, Spike N501Y, Spike Y505H, Spike T547K, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike N856K, Spike Q954H, Spike N969K, Spike L981F Size:

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

Price:

$1,490.00 – $2,350.00

SARS-CoV-2, Virus Like Particles (Wild Type)

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Size(s):

25 X 200 µL ~100 wells/96 well plate
60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Available upon request. Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications

Price:

$1,490.00 – $2,350.00

Sudan virus-like particles (SUDV VLP)

Sudan Virus-like particles (VLP’s) expressing recombinant Sudan virus (SUDV) glycoprotein (GP), nucleoprotein (NP), and matrix protein (VP40). These VLP’s are produced in Sf9 insect cells through infection with a recombinant baculovirus. Since these VLP’s mimic Sudan virus but do not contain genetic material, thus are not infectious and make an ideal candidate as a vaccine and also as a tool to enhance filovirus research.

Formulation & Storage: Supplied in PBS (supplemented with arginine and glutamic acid). Store at 2-3 weeks at -20°C, -80°C long term
Pathogen Strain: Boniface
Purification: Column chromatography
Expression: SF9 cells
Please note: After thawing, VLP’s tend to sediment to the bottom of the tube and appear as aggregate pellet. VLP’s can be resuspended by gentle vortexing or by pipetting up and down, before use. Also, subaliquoting is recommended to avoid repeated freeze/thaw cycles
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.